CSL Behring has identified what it will take to win in a major autoimmune market. Ahead of a potential approval of argenx’s rival drug, the company surveyed people with chronic inflammatory ...

Management reaffirmed guidance for fiscal 2025, expecting revenue growth of 5% to 7% and NPATA between AUD 3.2 billion to AUD 3.3 billion at constant currency. CSL Behring is anticipated to sustain ...

Feb 11 (Reuters) - Australian biopharmaceutical company CSL said on Tuesday that falling immunisation rates in the U.S., its largest market, weighed on its vaccine sales and first-half profit growth, ...

I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine ("Seqirus") and plasma therapy ("Behring") segments. Seqirus is witnessing revenue declines as a result of ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...